AAM

Sponsorship and exhibitor spots are now open for #GRxBiosims 2026! Connect with industry leaders, engage regulators, and generate real leads. Build your brand, grow your network, and stay ahead of policy shifts. Reserve your space today: grxbiosims.org

Intellectual property in pharmaceuticals: John Murphy, President and CEO of the Association for Accessible Medicines @AccessibleMeds, speaks with host @Andrew_Langer about monopolies and innovation.

“AAM is thankful to the President and the Administration for recognizing the importance and value generic and biosimilar medicines provide to American patients and we look forward to continuing to work together to advancing cost-saving solutions,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generics and Biosimilars are the single greatest area of potential savings for patents in the health care ecosystem.” Read full AAM comments on TrumpRx including generic medicines: accessiblemeds.org/resources/pres…

There is a lot of misinformation floating around when it comes to biosimilar medicines and interchangeability. Here's the bottom line: Interchangeable biologics ARE NOT superior versions of biosimilars. Unfortunately, the statutory distinction between biosimilars and interchangeable biosimilars continues to generate confusion and misinformation about the safety of biosimilar medicines. @US_FDA has consistently affirmed that there is no scientific difference between biosimilars and interchangeable biologics; and recently recommended that Congress remove this unnecessary distinction. The Biosimilar Red Tape Elimination Act is consistent with FDA’s science-based recommendation and represents an important step toward building confidence and streamlining patient access to biosimilar medicines. Learn more: biosimilarscouncil.org/interchangeabi… @AccessibleMeds

Rapid price deflation within the generic medicines market is threatening industry sustainability and patient care. Learn how we can protect patient access to lower-cost treatments: accessiblemeds.org/resources/blog… #GRxBiosimsSavingsReport

Is the Iran conflict impacting the pharmaceutical industry? Hear from John Murphy, President and CEO of @AccessibleMeds, with host @Andrew_Langer.

Speaker Announcement: Transparency Rising 2026 Featuring John Murphy III, President/CEO of the Association for Accessible Medicines John will take the stage for a panel discussion, sharing his expertise on building a more competitive biosimilar market. @AccessibleMeds

Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved American’s $467 billion—providing patients the health and financial outcomes necessary to thrive. accessiblemeds.org/resources/blog… #GRxBiosimsSavingsReport

Healthcare doesn’t stand still—and neither do the conversations shaping it. Join leaders at #GRxBiosims 2026 & #Access2027 to tackle policy, innovation, and patient access. Registration is open with early bird savings! ➡️ grxbiosims.org ➡️ accessiblemeds.org/events/access-…

#GRxBiosims brings together the leaders driving access and affordability in healthcare. Early Bird pricing is available for a limited time, giving you the best rate to join the industry’s most important conversations. Secure your spot and save: accessiblemeds.org/events/grxbios…

Statutory exclusivity vs. patent protection: John Murphy, President and CEO of the Association for Accessible Medicines @AccessibleMeds, explains the difference with host @Andrew_Langer.

Supporting generic medicine doesn't make you anti-innovation. John Murphy, President and CEO of the Association for Accessible Medicines @AccessibleMeds, speaks with host @Andrew_Langer about branded medicine and the cycle of innovation.

Why is generic medicine important? John Murphy, President and CEO of the Association for Accessible Medicines @AccessibleMeds, weighs in with host @Andrew_Langer.

Skinny Labels save patients money! Skinny labels are protected by law, cut costs while respecting innovation, and allow generic medicines to reach patients faster without infringing patents. But recent court decisions targeting skinny labeling threaten a decades-long pathway that has safely and legally lowered drug prices. Weakening this framework will delay market-entry for generics, reduce competition, and increase prices for patients. Actions must be taken to protect skinny labeling and preserve patient access to affordable generic medicines. Learn more on the timeliness of this issue, from @NPR: npr.org/2026/04/29/nx-… @NPRHealth @BiosimsCouncil

Here at AAM, we realize that effectively engaging with the @us_FDA is important for patient organizations. Join @foodanddruglaw on June 16–17 for 'Essentials of Working with FDA for Patient Organizations,' a practical program designed to help organizations navigate key regulatory processes. Learn more and register today: fdli.org/patientorg @BiosimsCouncil

In 2024, #generics & #biosimilars saved America’s patients and the U.S. healthcare system $467B—and $3.4T in the past 10 years. Learn more, including what can be done to help safeguard this important industry: accessiblemeds.org/resources/blog… #GRxBiosimsSavingsReport

Recently, @FederalNewswire @TheLunchHourPod, with host Andrew Langer, picked AAM CEO John Murphy III's brain on how important it is that regulators and lawmakers take swift action to protect patient access to lower-cost generic medicines. 'A major focus of the conversation is the growing tension between pharmaceutical innovation and affordability. Murphy breaks down how the current system of patents and exclusivity — originally designed to balance innovation with competition — has evolved in ways that can delay generic entry and extend high prices far beyond what was originally intended. Murphy also highlights the national security implications of the generic drug industry, arguing that access to affordable antibiotics, anti-infectives, and essential medicines is just as critical as breakthrough innovation.' WATCH: youtu.be/xOr_-Ny9t6A?si… @BiosimsCouncil

Check out this @FederalNewswire Lunch Hour Podcast, where our AAM CEO @JAMurphy_III explains why generics make up nearly 90% of prescriptions in the United States while accounting for only a fraction of total drug spending — and why that imbalance reveals deeper structural issues in how medicines are priced, patented, and brought to market. "A major focus of the conversation is the growing tension between pharmaceutical innovation and affordability... how the current system of patents and exclusivity — originally designed to balance innovation with competition — has evolved in ways that can delay generic entry and extend high prices far beyond what was originally intended. " LISTEN: podcasts.apple.com/us/podcast/ep-… @BiosimsCouncil